|
End-of-day quote
Taipei Exchange
18/09/2026
|
5-day change | 1st Jan Change | ||
| 165.50 TWD | -1.19% |
|
+1.22% | +316.88% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 137B 4.31B 3.76B 3.55B 3.22B 6.04B 414B 6.07B 42.53B 16.41B 210B 16.2B 15.84B 677B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 121B 3.8B 3.31B 3.13B 2.84B 5.32B 365B 5.35B 37.48B 14.46B 185B 14.28B 13.96B 597B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -1.19% | ||
| 1 week | +1.22% | ||
| Current month | +73.12% | ||
| 1 month | +84.92% | ||
| 3 months | +309.15% | ||
| 6 months | +339.58% | ||
| Current year | +316.88% |
| 1 week | 155 |  | 177 |
| 1 month | 82.2 | | 200 |
| Current year | 33.1 | | 200 |
| 1 year | 15.8 | | 200 |
| 3 years | 7 | | 200 |
| 5 years | 7 | | 200 |
| 10 years | 2.7 | | 200 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 31/05/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 24/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 12/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 26/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 26/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.19% | +1.22% | +900.00% | +1,284.94% | 4.31B | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,028B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 186B | |
| Average | +0.06% | +2.84% | +113.53% | +169.27% | 360.6B | |
| Weighted average by Cap. | +0.23% | +3.09% | +36.18% | +63.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -23.38M -20.39M -19.25M -17.48M -32.76M -2.24B -32.89M -231M -89M -1.14B -87.84M -85.89M -3.67B | -1.36B -42.82M -37.34M -35.26M -32.02M -59.98M -4.11B -60.23M -422M -163M -2.09B -161M -157M -6.72B |
| Net Debt | -5.17B -163M -142M -134M -122M -228M -15.6B -229M -1.6B -619M -7.93B -611M -597M -25.52B | -16.27B -511M -446M -421M -382M -716M -49.05B -719M -5.04B -1.95B -24.94B -1.92B -1.88B -80.24B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/26 | NT$165.50 | -1.19% | 6,684,329 |
| 17/09/26 | NT$167.50 | +2.76% | 6,144,246 |
| 16/09/26 | NT$163.00 | -3.26% | 10,020,716 |
| 15/09/26 | NT$168.50 | +0.90% | 10,795,882 |
| 14/09/26 | NT$167.00 | +2.14% | 8,557,027 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
